333 related articles for article (PubMed ID: 31513757)
21. Treatment of diffuse large B cell lymphoma.
Kwak JY
Korean J Intern Med; 2012 Dec; 27(4):369-77. PubMed ID: 23269875
[TBL] [Abstract][Full Text] [Related]
22. Primary Bone Lymphoma Exhibits a Favorable Prognosis and Distinct Gene Expression Signatures Resembling Diffuse Large B-Cell Lymphoma Derived From Centrocytes in the Germinal Center.
Li X; Xu-Monette ZY; Yi S; Dabaja BS; Manyam GC; Westin J; Fowler N; Miranda RN; Zhang M; Ferry JA; Medeiros LJ; Harris NL; Young KH
Am J Surg Pathol; 2017 Oct; 41(10):1309-1321. PubMed ID: 28817403
[TBL] [Abstract][Full Text] [Related]
23. Cost burden of diffuse large B-cell lymphoma.
Harkins RA; Patel SP; Flowers CR
Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):645-661. PubMed ID: 31623476
[No Abstract] [Full Text] [Related]
24. An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma.
Walji M; Assouline S
Expert Rev Hematol; 2020 Sep; 13(9):933-942. PubMed ID: 32700586
[TBL] [Abstract][Full Text] [Related]
25. Prognostic and therapeutic value of somatic mutations in diffuse large B-cell lymphoma: A systematic review.
Lopez-Santillan M; Lopez-Lopez E; Alvarez-Gonzalez P; Martinez G; Arzuaga-Mendez J; Ruiz-Diaz I; Guerra-Merino I; Gutierrez-Camino A; Martin-Guerrero I
Crit Rev Oncol Hematol; 2021 Sep; 165():103430. PubMed ID: 34339834
[TBL] [Abstract][Full Text] [Related]
26. [Molecular pathogenesis and treatment strategy in diffuse large B-cell lymphoma].
Shimada K
Rinsho Ketsueki; 2017; 58(10):2033-2042. PubMed ID: 28978846
[TBL] [Abstract][Full Text] [Related]
27. Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.
Ollila TA; Olszewski AJ
Curr Treat Options Oncol; 2018 Jun; 19(8):38. PubMed ID: 29931605
[TBL] [Abstract][Full Text] [Related]
28. Diffuse large B cell lymphoma CD5-positive arising in an immune deficiency and immune dysregulation setting: A case report and brief review of the literature.
Cristian M; Baz RA; Stoica AG; Așchie M; Ghinea MM; Deacu M; Boșoteanu M; Mitroi AF; Dobrin N; Iordache IE; Bălțătescu GI
Medicine (Baltimore); 2023 Feb; 102(8):e33083. PubMed ID: 36827036
[TBL] [Abstract][Full Text] [Related]
29. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.
Rasmussen PK
Acta Ophthalmol; 2013 Jul; 91 Thesis 5():1-27. PubMed ID: 24041159
[TBL] [Abstract][Full Text] [Related]
30. Deep learning-based classifier of diffuse large B-cell lymphoma cell-of-origin with clinical outcome.
Viswanathan A; Kundal K; Sengupta A; Kumar A; Kumar KV; Holmes AB; Kumar R
Brief Funct Genomics; 2023 Jan; 22(1):42-48. PubMed ID: 36412115
[TBL] [Abstract][Full Text] [Related]
31. Next-generation prognostic assessment for diffuse large B-cell lymphoma.
Staton AD; Koff JL; Chen Q; Ayer T; Flowers CR
Future Oncol; 2015; 11(17):2443-57. PubMed ID: 26289217
[TBL] [Abstract][Full Text] [Related]
32. Molecular subtyping of diffuse large B-cell lymphoma: update on biology, diagnosis and emerging platforms for practising pathologists.
Gifford GK; Gill AJ; Stevenson WS
Pathology; 2016 Jan; 48(1):5-16. PubMed ID: 27020203
[TBL] [Abstract][Full Text] [Related]
33. CD43 expression in diffuse large B-cell lymphoma, not otherwise specified: CD43 is a marker of adverse prognosis.
Ma XB; Zheng Y; Yuan HP; Jiang J; Wang YP
Hum Pathol; 2015 Apr; 46(4):593-9. PubMed ID: 25682152
[TBL] [Abstract][Full Text] [Related]
34. Genomic characterisation of diffuse large B-cell lymphoma.
Harrington F; Greenslade M; Talaulikar D; Corboy G
Pathology; 2021 Apr; 53(3):367-376. PubMed ID: 33642095
[TBL] [Abstract][Full Text] [Related]
35. Molecular Subtyping of Diffuse Large B-Cell Lymphoma Using a Novel Quantitative RT-PCR Assay.
Ta R; Santini C; Gou P; Lee G; Tai YC; O'Brien C; Fontecha M; Grant C; Bacon L; Finn S; Vandenberghe E; Quinn F; Dua R; Flavin R
J Mol Diagn; 2021 Mar; 23(3):323-340. PubMed ID: 33385586
[TBL] [Abstract][Full Text] [Related]
36. Rare cases of primary central nervous system anaplastic variant of diffuse large B-cell lymphoma.
Xu T; Jia Q; Wang Y; Liu Y; Han D; Li P; Ma J; Fan L; Yan Q; Guo S; Li M; Wang Z
Diagn Pathol; 2019 May; 14(1):45. PubMed ID: 31109360
[TBL] [Abstract][Full Text] [Related]
37. Prognostication of diffuse large B-cell lymphoma in the rituximab era.
Ninan MJ; Wadhwa PD; Gupta P
Leuk Lymphoma; 2011 Mar; 52(3):360-73. PubMed ID: 21275631
[TBL] [Abstract][Full Text] [Related]
38. Molecular profiling in diffuse large B-cell lymphoma: why so many types of subtypes?
Morin RD; Arthur SE; Hodson DJ
Br J Haematol; 2022 Feb; 196(4):814-829. PubMed ID: 34467527
[TBL] [Abstract][Full Text] [Related]
39. Using the pathology report in initial treatment decisions for diffuse large B-cell lymphoma: time for a precision medicine approach.
Friedberg JW
Hematology Am Soc Hematol Educ Program; 2015; 2015():618-24. PubMed ID: 26637779
[TBL] [Abstract][Full Text] [Related]
40. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.
Hu S; Xu-Monette ZY; Balasubramanyam A; Manyam GC; Visco C; Tzankov A; Liu WM; Miranda RN; Zhang L; Montes-Moreno S; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Han van Krieken J; Huang Q; Huh J; Ai W; Ponzoni M; Ferreri AJ; Zhao X; Winter JN; Zhang M; Li L; Møller MB; Piris MA; Li Y; Go RS; Wu L; Medeiros LJ; Young KH
Blood; 2013 Apr; 121(14):2715-24. PubMed ID: 23343832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
